Radiation therapy for prostate cancer: What’s the best in 2021

Abstract

Radiotherapy is highly involved in the management of prostate cancer. Its features and potential applications experienced a radical evolution over last decades, as they are associated to the continuous evolution of available technology and current oncological innovations. Some application of radiotherapy like brachytherapy have been recently enriched by innovative features and multidisciplinary dedications. In this report we aim to put some questions regarding the following issues regarding multiple aspects of modern application of radiation oncology: the current application of radiation oncology; the modern role of stereotactic body radiotherapy (SBRT) for both the management of primary lesions and for lymph-nodal recurrence; the management of the oligometastatic presentations; the role of brachytherapy; the aid played by the application of the organ at risk spacer (spacer OAR), fiducial markers, electromagnetic tracking systems and on-line Magnetic Resonance guided radiotherapy (MRgRT), and the role of the new opportunity represented by radiomic analysis.

Magnetic resonance guided SBRT reirradiation in locally recurrent prostate cancer: a multicentric retrospective analysis

“…Nevertheless, the possibility to early diagnose it and the recent advancements of treatment strategies are changing the framework of the management of this disease with promising outcomes [ 2 ].…”

Late Adverse Health Outcomes and Quality of Life after curative radiotherapy + long-term ADT in Prostate Cancer Survivors: Comparison with men from the general population

“…However, with rising target doses the risk of urinary, bowel and sexual Adverse Health Outcomes (AHOs) (“typical AHOs”) increases, with eventual negative impact on Quality of Life (QoL). New radiotherapy (RT) techniques such as Intensity- modulated radiotherapy (IMRT), Image Guided Radiotherapy, Volumetric Modulated Arc Therapy (VMAT) and new brachytherapy techniques are expected to reduce this risk [1] .…”

A Novel L-Phenylalanine Dipeptide Inhibits the Growth and Metastasis of Prostate Cancer Cells via Targeting DUSP1 and TNFSF9

“…The global male cancer statistics report that was released by the International Agency for Research on Cancer (IARC) showed that prostate cancer (PCa) ranked second in male incidence and became the most common form of malignant tumor [1][2][3][4]. Currently, the treatment for PCa patients is mainly drug therapy [5], radical prostatectomy [6], radiotherapy [7,8], chemotherapy [9], and endocrine therapy [10], but often, these face severe challenges such as poor efficacy, complications, and drug resistance. As an essential source of drugs, natural products could be an alternative strategy for preventing and treating cancer diseases.…”